103 related articles for article (PubMed ID: 29590722)
1. Association of Pentraxin-3, Galectin-3 and Matrix Metalloproteinase-9/Timp-1 with Cardiovascular Risk in Renal Disease Patients.
Miljković M; Stefanović A; Bogavac-Stanojević N; Simić-Ogrizović S; Dumić J; Černe D; Jelić-Ivanović Z; Kotur-Stevuljević J
Acta Clin Croat; 2017 Dec; 56(4):673-680. PubMed ID: 29590722
[TBL] [Abstract][Full Text] [Related]
2. Value of pentraxin-3 and galectin-3 in acute coronary syndrome: a short-term prospective cohort study.
George M; Shanmugam E; Srivatsan V; Vasanth K; Ramraj B; Rajaram M; Jena A; Sridhar A; Chaudhury M; Kaliappan I
Ther Adv Cardiovasc Dis; 2015 Oct; 9(5):275-84. PubMed ID: 25814534
[TBL] [Abstract][Full Text] [Related]
3. Serum tissue-degrading proteinases and incident cardiovascular disease events.
Tuomainen AM; Kormi I; Havulinna AS; Tervahartiala T; Salomaa V; Sorsa T; Pussinen PJ
Eur J Prev Cardiol; 2014 Jul; 21(7):806-12. PubMed ID: 23079500
[TBL] [Abstract][Full Text] [Related]
4. Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress.
Pawlak K; Pawlak D; Mysliwiec M
Cytokine; 2005 Jul; 31(1):18-24. PubMed ID: 15896974
[TBL] [Abstract][Full Text] [Related]
5. The association of serum inflammatory biomarkers with chronic kidney disease in hypertensive patients.
Xu TY; Zhang Y; Li Y; Zhu DL; Gao PJ
Ren Fail; 2014 Jun; 36(5):666-72. PubMed ID: 24575880
[TBL] [Abstract][Full Text] [Related]
6. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3 (Gal-3) and the tissue inhibitor of matrix metalloproteinase (TIMP-2) as potential biomarkers for the clinical evolution of chronic Chagas cardiomyopathy.
Menezes CADS; de Oliveira ALG; Barbosa ICM; de Jesus ACP; Chaves AT; Rocha MODC
Acta Trop; 2024 Apr; 252():107153. PubMed ID: 38373528
[TBL] [Abstract][Full Text] [Related]
8. Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study.
Peeters SA; Engelen L; Buijs J; Jorsal A; Parving HH; Tarnow L; Rossing P; Schalkwijk CG; Stehouwer CDA
Cardiovasc Diabetol; 2017 Apr; 16(1):55. PubMed ID: 28446168
[TBL] [Abstract][Full Text] [Related]
9. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
[TBL] [Abstract][Full Text] [Related]
10. Relationship of interleukin-23 with matrix metalloproteinase-9, pentraxin-3, sleep quality and prostate size in benign prostatic hyperplasia.
Navaneethakannan M; Nandeesha H; Sreenivasan SK
Andrologia; 2022 Jun; 54(5):e14387. PubMed ID: 35092070
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
12. Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis.
Sanders JS; Huitema MG; Hanemaaijer R; van Goor H; Kallenberg CG; Stegeman CA
Am J Physiol Renal Physiol; 2007 Dec; 293(6):F1927-34. PubMed ID: 17898039
[TBL] [Abstract][Full Text] [Related]
13. Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.
Lu LC; Yang CW; Hsieh WY; Chuang WH; Lin YC; Lin CS
Clin Exp Nephrol; 2016 Dec; 20(6):934-942. PubMed ID: 26711243
[TBL] [Abstract][Full Text] [Related]
14. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease].
Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q
Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301
[TBL] [Abstract][Full Text] [Related]
15. Plasma matrix metalloproteinase-9 levels, MMP-9 gene haplotypes, and cardiovascular risk in obese subjects.
Luizon MR; Belo VA; Fernandes KS; Andrade VL; Tanus-Santos JE; Sandrim VC
Mol Biol Rep; 2016 Jun; 43(6):463-71. PubMed ID: 27146834
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study.
Peeters SA; Engelen L; Buijs J; Chaturvedi N; Fuller JH; Schalkwijk CG; Stehouwer CD;
Cardiovasc Diabetol; 2015 Mar; 14():31. PubMed ID: 25848912
[TBL] [Abstract][Full Text] [Related]
17. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality.
Tong M; Carrero JJ; Qureshi AR; Anderstam B; Heimbürger O; Bárány P; Axelsson J; Alvestrand A; Stenvinkel P; Lindholm B; Suliman ME
Clin J Am Soc Nephrol; 2007 Sep; 2(5):889-97. PubMed ID: 17702732
[TBL] [Abstract][Full Text] [Related]
18. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
Nakamura T; Matsuda T; Suzuki Y; Ueda Y; Koide H
ASAIO J; 2003; 49(4):430-4. PubMed ID: 12918586
[TBL] [Abstract][Full Text] [Related]
19. Increased plasma matrix metalloproteinase-2 (MMP-2), tissue inhibitor of proteinase-1 (TIMP-1), TIMP-2, and urine MMP-2 concentrations correlate with proteinuria in renal transplant recipients.
Mazanowska O; Zabińska M; Kościelska-Kasprzak K; Kamińska D; Krajewska M; Banasik M; Madziarska K; Zmonarski SC; Chudoba P; Biecek P; Boratyńska M; Klinger M
Transplant Proc; 2014 Oct; 46(8):2636-9. PubMed ID: 25380883
[TBL] [Abstract][Full Text] [Related]
20. Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Atherosclerosis; 2007 Jan; 190(1):199-204. PubMed ID: 16510149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
